

#20  
DEC 04 2001

RECEIVED

TECH CENTER 1600/2900

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: **Roderic M.K. DALE, et al.**  
Title: **METHOD FOR NUCLEIC ACID PREPARATION**  
Appl. No.: **09/223,957**  
Filing Date: **December 31, 1998**  
Examiner: **H. Owens**  
Art Unit: **1623**



**DECLARATION OF STEVEN L. GATTON**  
**UNDER 37 C.F.R. § 1.132**

Dear Sir:

1. I, STEVEN L. GATTON, declare and say I am a resident of Lake Oswego, Oregon. My address is 18990 SW Pilkington Road, Lake Oswego, Oregon 97035-8130 U.S.A.
2. I hold a Bachelor degree in chemistry which I received from Muskingum College in May, 1976. I further hold an M.S. in chemistry which I received from Bowling Green State University in June, 1982. I am currently employed in the position of Director, Quality Assurance, and Safety/Chemical Hygiene Officer at the company Oligos Etc., Inc., 9775 SW Commerce Circle, Building C6 Wilsonville, Oregon 97070-0727. I am an expert in the fields of nucleic acid chemistry and oligonucleotide production and purification.
3. I am an inventor of the claims of the above-identified patent application. I directed others and personally performed the research leading to the invention disclosed and claimed therein.
4. I have read the Final Office Action dated August 17, 1999.
5. The following provides the evidence requested by the Examiner.

**Summary of Hamilton PRP-1 vs Waters Prep C18**

C18 columns and PRP-1 columns were compared for capacity limitations and efficacy in desalting and concentrating oligonucleotides following purification procedures. The columns used for this study, both C18 and PRP-1, were prepared using Millipore-Amicon Vantage 1.6 cm ID glass columns, poured to a height of 30 cm. Column volume of each column was calculated to be 60 mL.

The following results were obtained:

- A. The Waters Prep C18 stationary phase cannot be used to load samples from an alkaline (pH 10-14) SAX purification without first being neutralized to less than pH 8. This introduces an additional step into the process which the PRP does not require. As such Examples 1 and 2 cannot be performed using the C18 phase without modifying the protocol by adding an additional neutralization step. In addition, it has been reported (Sofer et al., *Process Chromatography: A Practical Guide*, Academic Press, San Diego, California (1989), p. 93-105, copy provided for Examiner) that chromatography media that are compatible with sodium hydroxide at elevated pH are most suitable for production-scale work. This allows sanitization of the chromatography phase without the use of bacteriostatic additives. High pH (13-14) is also capable of removing endotoxins from chromatography media. Since this is within the PRP-1 working pH range and well outside that of the Prep C18, the PRP has a clear advantage over the Prep C18 for large-scale processes used for drug manufacture.
- B. The pH range of the Waters Prep C18 phase as determined by the manufacturer not only does not permit the direct use of alkaline pH during loading, but it also precludes use of the C18 phase in acidification of acid-resistant oligonucleotides as demonstrated in Example 3. The pH of the acidifying solution is 1.5, which is below the lower limit of pH 3 of the C18. In addition, the typical loading range of oligonucleotide onto the PRP increases over 3-fold when performed at pH 1-2 rather than at pH 7. As written, Example 3 cannot be done on the Waters Prep C18 without sustaining damage to the phase. Example 3 is quite simple to perform using PRP phase.
- C. The Waters Prep C18 phase leaches absorbed oligonucleotide during the wash that is intended to remove residual salt from the SAX purification. This makes the determination as to when the salt has been removed problematic. The PRP cleanly holds its absorbed material, and allows the column to be washed to very low levels of conductivity without loss of material. This feature makes the PRP much easier for the operator and/or automated equipment to assess the endpoint of the washing process and to start the elution.
- D. The Waters Prep C18 is not compatible with the water-ethanol solvent system as practiced in all Examples of the application. The packing of the C18 columns used in this study cracked and channeled very badly during the elution. As a result, the columns required repacking before subsequent use. This problem has not been observed with the PRP, and columns have used for dozens of procedures without repacking.

E. Finally, the PRP column was able to retain a capacity of 4788 A<sub>260</sub> for a 40-mer, compared to only 2880 A<sub>260</sub> for a 40-mer with the C18 column. Thus the PRP column had a capacity 60% greater than the C18 column of approximately the same size and volume. This is a significant advantage in large scale production of oligonucleotides, as the fewer and/or smaller PRP columns would be required to desalt and concentrate synthesized oligonucleotides in large-scale preparations.

To summarize these results, the side-by-side comparison of the two columns are as follows:

<u>stationary phase</u>	<u>Acid resistant</u>	<u>Base resistant</u>	<u>Operating pH Range</u>	<u>Capacity of 40-mer</u>	<u>Leaching during wash</u>
PRP-1	Yes	Yes	0-14	4788 A <sub>260</sub>	No
C18	No	No	3-8	2880 A <sub>260</sub>	Yes

Thus, the PRP columns provide improved and unexpected results as exhibited by results including 1) improved pH range of use; 2) increased capacity; and 3) decreased leaching during the wash step as compared to the C18 columns.

6. I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title XVIII of the United States Code, and that such will false statements may jeopardize the validity of the application or any patent issuing thereon.

Date

8/23/2001

  
Steven L. Gatton



**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

**Applicant:** Roderie M.K. DALE, *et al.*  
**Title:** METHOD FOR NUCLEIC ACID  
 PREPARATION  
**Appl. No.:** 09/223,957  
**Filing Date:** December 31, 1998  
**Examiner:** H. Owens  
**Art Unit:** 1623

**REVOCATION OF PRIOR POWERS OF ATTORNEY BY ASSIGNEE**  
**APPOINTMENT OF NEW POWER OF ATTORNEY BY ASSIGNEE**  
**CHANGE OF CORRESPONDENCE ADDRESS**

Commissioner for Patents  
 Washington, D.C. 20231

Sir:

Oligos Etc., Inc. is the assignee of Application No. 09/223,957 filed December 31, 1998, and all continuing applications thereof, as evidenced by an Assignment recorded in the U.S. Patent and Trademark Office on October 28, 1999 at reel/frame 010344/0214.

Oligos Etc., Inc., through its duly-delegated representative, hereby revokes all prior Powers of Attorney submitted in this application, and hereby appoints the following registered attorneys and agents of the law firm of FOLEY & LARDNER:

STEPHEN A. BENT	Reg. No. 29,788
DAVID A. BLUMENTHAL	Reg. No. 26,257
BETH A. BURROUS	Reg. No. 35,087
ALAN I. CANTOR	Reg. No. 28,183
WILLIAM T. ELLIS	Reg. No. 20,874
JOHN J. FELDHAUS	Reg. No. 28,822
MICHAEL D. KAMINSKI	Reg. No. 32,904
LYLE K. KIMMS	Reg. No. 34,079
KENNETH E. KROGIN	Reg. No. 25,735
JOHNNY A. KUMAR	Reg. No. 34,049
JACK LAHR	Reg. No. 18,821
GLENN LAW	Reg. No. 34,371
PETER G. MACK	Reg. No. 26,001
STEPHEN B. MAEBUS	Reg. No. 35,264
BRIAN J. MC NAMARA	Reg. No. 32,789
SYBIL MELOY	Reg. No. 22,740
RICHARD C. PEET	Reg. No. 35,792

GEORGE E. QUILLIN  
ANDREW E. RAWLINS  
BERNHARD D. SAXE  
CHARLES F. SCHILL  
RICHARD L. SCHWAA8  
MICHELE M. SIMKIN  
HAROLD C. WEGNER

Reg. No. 32,792  
Reg. No. 34,702  
Reg. No. 28,885  
Reg. No. 27,880  
Reg. No. 28,479  
Reg. No. 34,717  
Reg. No. 28,288

as its principal attorneys to have full power to prosecute this application and any continuations, divisions, reissues, and reexaminations thereof, to receive the patent, to transact all business in the United States Patent and Trademark Office connected therewith, and to have full power of substitution, association, and revocation, including the power to revoke the power of attorney of any associate attorney.

Please direct all future correspondence concerning this application to:

Beth A. Burrows  
FOLEY & LARDNER  
Washington Harbour  
3000 K Street, N.W., Suite 500  
Washington, D.C. 20007-5108

Telephone: (202) 672-8475  
Facsimile: (202) 672-5399

Executed this 6<sup>th</sup> day of June, 2001.

Oligos Etc., Inc.

By:

Roderic M. K. Dale

(Signature)

Roderic M. K. Dale

(Printed Name)

CEO

(Title)